We mentioned this — as a rumor piece, a few weeks ago. And the Organon NYSE common stock price is now up almost 100% — since the morning before the rumor piece floated through various financial outlets, that week. It does seem like a pretty high price for these very mature brands. But we shall, as ever see.
In any event, here’s FiercePharma’s finely cogent take on it all, from while I was in the air yesterday:
…Already the largest biopharma company in India, generics powerhouse Sun Pharma has doubled in size with its acquisition (PDF) of women’s health leader Organon. With its $11.75 billion buyout, Sun has picked up a drugmaker that matched the $6.2 billion in sales that it generated in 2025.
Sun is paying $14 per share, which is a 24% premium on Organon’s closing price on Friday. It is also a more than 100% premium on Organon’s share price at the start of April. With the agreement, which is expected to close by early 2027, Sun’s stock increased by 7%, while Organon’s jumped by 17%.
The deal, which is the largest ever by an Indian biopharma, the company said, will boost Sun’s portfolio of innovative medicines and will catapult it to No. 7 among the world’s top sellers of biosimilars, the company said in its release….
Organon’s stock had been weighed down by “heavy headwinds,” according to Evercore ISI analyst Umer Raffat, citing the New Jersey company’s debt, its oncoming loss of exclusivity of contraceptive implant Nexplanon and its “bad M&A to digest,” which is a reference to Organon’s $1.2 billion 2024 buyout of Dermavant….
Now you know — even if I’m a little out of date.
Onward — with travel ahead, on each of the next three weekends — with one more half-marathon toward the end — and Colorado and points eastward, too. Woot!
नमस्ते
Powerline Lies... 